The large number of recent publications concerning the inter-relationships between the central nervous system and the anterior pituitary testifies to the intense interest in this subject (2, 3). Particular attention has been devoted to the effects of hypothalamic stimulation or injury upon pituitary ACTH release and adrenal cortical response. The work of deGroot and Harris (4), Hume and
(Submitted for publication October 12, 1956 ; accepted December 13, 1956) The large number of recent publications concerning the inter-relationships between the central nervous system and the anterior pituitary testifies to the intense interest in this subject (2, 3) . Particular attention has been devoted to the effects of hypothalamic stimulation or injury upon pituitary ACTH release and adrenal cortical response. The work of deGroot and Harris (4), Hume and Wittenstein (5), Porter (6) , McCann (7) , and many others has indicated the importance of hypothalamic integrity in the normal release of adrenocorticotropin from the pituitary in response to a stimulus.
Another approach to the problem of neural control of the pituitary has been made through the use of central nervous system-depressant drugs such as morphine (8) , which reportedly exerts an inhibitory influence upon pituitary release of corticotropin in response to acute stressing procedures. 'Among the drugs so used is the phenothiazine derivative, 10-(y-dimethylaminopropyl) -2-chlorophenothiazine ("largactil," chlorpromazine). A major site of action of this agent has been thought to be the hypothalamus (9) . Some weight was lent to this supposition by the finding of Wase, Christensen, and Polley that chlorpromazine labeled with S35 was accumulated in the hypothalamus in concentrations exceeding those attained in other areas of the brain (10) .
Reports of the effect of this drug upon the adrenal response (and by inference, upon the hypothalamic-pituitary-adrenal response) to various 1 Supported in part by a grant to Dr. Joseph W. Jailer from the National Institute of Arthritis and Metabolic Diseases (A-195 [C] ). These data were presented in preliminary form at the 38th Annual Meeting of the Endocrine Society, June, 1956 (1) . 2 John and Mary R. Markle Scholar in Medical Science. (9) .
Three to 17 days after the chlorpromazine experiment was performed in a given patient, the procedure was repeated without chlorpromazine.
In eight of the nine patients, blood specimens for glucose determination were obtained at 0 time (6:30 a.m.) and 3 hours after insulin administration.
2. Effect of chlorpromazine upon response of the adrenal cortex to exogenous ACTH. In order to rule out the possibility that chlorpromazine might exert an effect upon adrenal cortical response to ACTH, patients treated with the drug in large doses (400 to 1,000 mg. per day) for periods of 25 to 70 days were subjected to standardized intravenous ACTH tests in a manner previously described (22) , the index of response again being the rise in plasma 17-OH-corticosteroid levels.
In addition, three patients received chlorpromazine acutely, with a dose schedule like that employed in the insulin coma studies, and then were subjected to intravenous ACTH tests.
3. Analytical methods. Levels of plasma 17,21-dihydroxy-20-ketosteroids were estimated by the SilberPorter method (23) , as modified in this laboratory (24) , and more recently, by a procedure which incorporated the essential features of the changes made by Peterson, Wyngaarden, Guerra, Brodie, and Bunim (25) and which eliminates the need for adding cortisol to the unknowns.
Blood glucose determinations were made according to the method of Benedict (26) .
For more specific measurement of plasma 17-OH-corticosteroids, paper chromatography was resorted to. This was deemed necessary because it was noticed as the study progressed that a pink color formed in the blank tubes of plasma samples taken from patients who had received large doses of chlorpromazine. In titro studies revealed that this chromogen was due to chlorpromazine and that it also interfered with optimal development of PorterSilber chromogen, i.e., with the development of the color reaction between cortisol and phenylhydrazine-sulfuric acid. Readings were reduced, at most, to values 15 per cent below control levels in in vitro experiments in which chlorpromazine in amounts equivalent to 250 micrograms per 100 ml. plasma was added to known amounts of cortisol. 4 Attempts to separate chlorpromazine from corti-'No reliable quantitative data are yet available concerning the plasma levels of chlorpromazine attained in human subjects given the usual doses of the drug (9) . sol in vitro and in vivo by washing extracts with 1 N sulfuric acid (9) and by means of column chromatography (18) were not successful.
Separation was achieved by paper chromatography.
Plasma was extracted with ethyl acetate, washed with base, subjected to hexane: methanol partition, and the dried extract chromatographed in a formamide: chloroform system as described by Burton, Zaffaroni, and Keutmann (27) . The Plasma samples which were subjected to these extraction and chromatographic procedures were obtained from 12 additional patients with insulin coma. Large samples of blood were drawn at 3 and at 4 hours, and the two specimens from a given patient pooled together. Quantitation of post-insulin cortisol levels in the group receiving only insulin was compared with quantitation of the steroid in the group receiving insulin plus chlorpromazine.
The figure, 250 micrograms per 100 ml. plasma, was arrived at after trial and error as a quantity which produced the pink chromogen to a degree greater than that encountered in plasma specimens obtained from the chlorpromazine-treated subjects. Plasma concentrations in the patients were therefore assumed to be less than 250 micrograms per 100 ml. The validity of that assumption appears to be borne out by data presented in a study published since the preparation of this report (Salzman, N Table I . It will be seen that resting levels fell within the normal range (4 to 28 micrograms per 100 ml. [24] ), and at 3 and at 4 hours after insulin there was a consistent rise to mean levels of 34 and 42 micrograms per 100 ml., respectively. These levels were above the normal range and were roughly comparable to levels attained by normal individuals following intravenous administration of 25 i.u. ACTH (22) . There appeared to be no correlation between the magnitude of plasma 17-OHcorticosteroid rise and the size of the dose of insulin.
Effect of chlorpromazine upon plasma 17-OHcorticosteroid response to insulin coma Table II shows the results in the same patients pre-treated with chlorpromazine. It is apparent that the resting levels of plasma 17-OH-corticosteroids were comparable to those found in the control experiments (mean levels, 20 and 22 micrograms per 100 ml., respectively). In contrast to the control responses, 17-OH-corticosteroid levels during coma did not rise, but remained 5This dose was arrived at by purely empirical means, being the dose required to produce satisfactory coma which was not unduly prolonged. The required dose was extremely variable from patient to patient, and tended in most cases to become progressively smaller during the course of the series of coma treatments. within normal limits. The trend of values was reminiscent of the normal diurnal variation of plasma 17-OH-corticosteroid levels observed by Bliss, Sandberg, Nelson, and Eik-Nes (30) . The duration and depth of coma did not appear to differ from the coma seen during the control experiments without chlorpromazine. The only clinical differences noted were diminution of salivation and sweating in the chlorpromazine-treated group. No differences in depression of blood pressure were found.
In the repeat control experiments, plasma 17-OH-corticosteroid levels rose as they had in the initial controls in six of eight subjects (Table  III) . The data from control and chlorpromazine experiments in four of the patients are presented graphically in Figure 1 .
In two additional patients, chlorpromazine did not clearly inhibit the adrenal cortical response to insulin. Since the control rises in plasma 17-OHcorticosteroid levels were also equivocal, it was thought reasonable to exclude the findings in these cases from the data presented.
As shown in Table IV , depressions of blood glucose in the control and chlorpromazine studies did not differ appreciably.
Chromatographic studies of plasma 17-OH-corticosteroids during insulin coma Table V summarizes the results of chromatographic fractionation and quantitation of plasma cortisol levels. In the Table are amounts of cortisol detected during insulin coma with and without chlorpromazine pre-treatment. Without chlorpromazine, the mean value for plasma cortisol after chromatography was 18.0 micrograms per 100 ml. (without chromatography, 34.6 micrograms per 100 ml.; "recovery," 52 per cent). In the chlorpromazine-treated subjects, the average value was 8.7 micrograms per 100 ml. (without chromatography, 16.7 micrograms per 100 ml.; "recovery," 52 per cent). The difference between the means of the two groups was statistically significant (P < 0.01). The fact that about the same proportion of cortisol was recovered in control and chlorpromazine experiments after chromatography lessened the suspicion that the difference in cortisol levels could be accounted for by an adverse effect of chlorpromazine itself upon steroid recovery. This already seemed unlikely from in vitro studies (cf. Section 3, Methods and Materials).
Effect of chlorpromazine upon plasma 17-OHcorticosteroid response to exogenous ACTH Table VI shows the effects of long-and shortterm chlorpromazine administration upon the response of the adrenal cortex to exogenous ACTH. It is obvious that only one of the patients (A. T.) showed a very slightly reduced response. Despite the inhibitory effect of the drug upon plasma corticosteroid response to insulin, it did not bring about a suppression of ACTH-responsiveness of the adrenal cortex as does prolonged steroid administration (31) . Similarly, acute administration of the drug, given according to the dose schedule used in the insulin studies, had no suppressive effect upon the response to ACTH.
DISCUSSION
The data presented confirm the efficacy of insulin hypoglycemia as a stimulus to the adrenal cortex in man (20) . The (Table II ), yet adrenocortical response still occurs in a manner comparable to initial controls (Table I) .
that chlorpromazine can inhibit the adrenocortical reaction to this stimulus. The inhibition of plasma 17-OH-corticosteroid rise after insulin which was caused by chlorpromazine does not seem to be an artifact. Chromatographic separation and quantitation of steroid revealed that cortisol in plasma of the chlorpromazine-treated subject was reduced by about 50 per cent in comparison with the control. This was essentially the same degree of reduction found in unchromatographed plasma specimens. The results appear to support those of certain previous investigations in animals (11) (12) (13) (14) . The absence of definite blockade of adrenal cortical response reported by other workers (15) (16) (17) may perhaps be explained by differences in dosage and in timing of administration of the drug in relation to the stimulus imposed, as Hamburger has suggested (12) . The findings presented here and earlier (11) (12) (13) (14) are not necessarily incompatible with the adrenocortical-stimulating property of chlorpromazine demonstrated by Hamburger (12) , by Egdahl, Richards, and Hume (18) , and by Harwood (19) . The factors of speed and route of administration may play a role, and as Harris has pointed out, chlorpromazine may be to some extent a toxic compound like other "blocking agents" which have been used in similar experiments and which themselves cause corticotropin release (2) .
This experiment does not elucidate the mechanism of the demonstrated blocking action of chlorpromazine. It seems clear from the findings presented here and from the work of Olling and deWied (14) that the drug does not interfere with the action of adrenocorticotropin upon the adrenal cortex itself. There is no experimental precedent to suggest that this agent can cause an increased rate of disappearance of cortisol from plasma, or accelerated hepatic reduction and conjugation of cortisol. To date, an increased rate of cortisol disposal has been demonstrated only in hyperthyroidism (25) .
In trying to visualize the mechanism of the blockade, one is tempted to assume that the site of action of chlorpromazine in inhibiting adrenocortical response (and by inference, pituitary corticotropin release) might be the hypothalamus. Some support for this assumption might be derived from the known suppressive effects of chlorpromazine upon the hypothalamus (9) , from the moderately selective accumulation of chlorpromazine in hypothalamic structures (10) , and from the knowledge that experimental damage to certain hypothalamic nuclei may result in inhibition of ACTH release in response to a stimulus (4) (5) (6) (7) . However, such a chain of reasoning must be viewed as entirely speculative, and it should be realized that the data presented in this report, which might be construed as supporting such a concept, constitute only indirect and circumstantial evidence.
The fact that relatively prolonged administration of chlorpromazine failed to suppress plasma 17-OH-corticosteroid response to exogenous ACTH (in contrast to long-term steroid administration [31] ) is not necessarily incompatible with the inhibitory effect of the drug upon adrenal cortical response to an acute stimulus. The two apparently contradictory findings may perhaps be reconciled by Harris' concept of a dual control of the central nervous system over corticotropin release, one mechanism operating under quiescent conditions, the other under conditions of "stress" (2) . Such an explanation is again speculative, and it is emphasized that the above discrepancy cannot be satisfactorily accounted for on the basis of present information.
Finally,, it is perhaps of some importance that, however produced, blockade of adrenal cortical response to the rather severe stress of insulin hypoglycemia did not result in any clinical symptoms suggesting adrenal cortical insufficiency. Similar observations were made when adrenal cortical response to typhoid vaccine administration was prevented by blocking the pyrogenic reaction with aminopyrine (32) . These findings may be interpreted as supporting the concept of the "permissive" role of the adrenal cortex in homeostasis as stated by Ingle (33) , and again raise a question as to the advantage for the organism of large increases in adrenal cortical activity in response to acute stimuli. SUMMARY 1. Insulin coma was again shown to cause adrenal cortical response in man, as measured by rises in plasma 17-OH-corticosteroid levels.
2. Chlorpromazine usually inhibited this adrenal cortical response to insulin hypoglycemia.
3. Chlorpromazine had no inhibitory effect upon the response of the human adrenal cortex to administered adrenocorticotropin.
